Jun 21, 2022

Disclosures: Moore reports institutional research fundings from AstraZeneca, Daiichi Sankyo, Roche and Sermonix Pharmaceuticals. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio CHICAGO — Halle Moore, MD, director of breast medical oncology in the department of hematology and oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about findings from the ELAINE 2 study. Results from the study, which assessed a combination of lasofoxifene and abemaciclib in pre- and postmenopausal patients who had ER-positive/HER2-negative metastatic breast cancer and an ESR1 mutation , were presented at ASCO Annual Meeting. “In this trial, in participants who had progression following prior endocrine therapies as well as... up to one line of prior chemotherapy, the combination appeared to be very well tolerated,” Moore said. “Side effects were largely related to the abemaciclib and included gastrointestinal toxicity and cytopenias.” She added that two instances of thrombosis occurred among patients included in the study. “Impressively, however, was the median progression-free survival of 13.9 months that was seen in this refractory metastatic breast cancer population with ESR1 mutations,” Moore said. “So, we were very impressed with the duration of response and the clinical benefit rate in about two-thirds of the patients, who did not have disease progression in the first 24 weeks.” Read more about